Physician profile
Yun Hu
NPI 1245376755
$2,578.34
in general payments reported to CMS, 2019-2025
20 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $117 · 2021: $296 · 2022: $473 · 2023: $525 · 2024: $524 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.38 | 2022-2025 | |
| Alcon Vision LLC | $374.93 | 2019-2025 | Clareon, Centurion, Unity |
| Regeneron Healthcare Solutions, INC. | $304.57 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $302.78 | 2020-2022 | |
| Glaukos Corporation | $297.75 | 2019-2025 | Istent Infinite, Idosetr |
| Genentech USA, INC. | $198.54 | 2022-2025 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $165.64 | 2024-2025 | Xdemvy |
| Rxsight INC | $119.00 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $72.67 | 2020-2021 | |
| Amgen INC. | $60.29 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $45.39 | 2021-2023 | Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.15 | 2019-2020 | |
| Iridex Corporation | $35.25 | 2021 | |
| Kala Pharmaceuticals, INC. | $35.21 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $32.46 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $30.80 | 2024 | Xeomin |
| Bausch & Lomb Americas INC. | $18.51 | 2024 | Vyzulta |
| Ocular Therapeutix, INC. | $17.40 | 2024 | Dextenza |
| Shire North American Group INC | $12.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.